Why AdaptHealth Stock Plummeted This Week

AdaptHealth (AHCO) shares fell 47% on the week after reporting a major Q2 miss: EPS of -$1.07 vs a $0.15 analyst target, and sales up 12.7% YoY to $740.3M but $106.5M below expectations. The company sharply cut full-year guidance, lowering sales to $2.85B–$2.89B from $3.45B–$3.52B and reducing EBITDA to $490M–$520M (from $680M–$730M) and FCF to $80M–$120M (from $175M–$225M). The combination of earnings deterioration and large guidance reset signals heightened execution risk.

Analysis

This is less a simple earnings miss than a credibility event: when a scaled operator in a reimbursement-sensitive niche loses both earnings power and forward cash generation at the same time, the market usually re-prices the equity as a balance-sheet story, not a growth story. That matters because fixed-cost businesses in DME/home respiratory have ugly operating leverage; if referral volume or payer mix slips even modestly, margin compression can continue long after the headline quarter.

The near-term winners are better-capitalized channel participants that can absorb share and negotiate from a position of strength. Over the next 1-3 months, watch whether competitors or adjacent suppliers see incremental volume as providers and insurers reroute orders away from a stressed operator; the second-order effect is often tighter working-capital terms and slower payment cycles for weaker names. If the guide reset is mostly accounting optics from a divestiture, the stock can bounce, but if organic demand is deteriorating, the downside extends well beyond one quarter.

The consensus may be underestimating how much of the stock’s value was premised on a steady deleveraging path. A lower FCF trajectory raises the cost of capital and can force management into defensive moves that suppress growth investments, which is usually when franchise quality starts to leak into market share. The contrarian tell would be a stabilization in organic revenue and cash conversion on the next update; absent that, this is still a falling-knife setup rather than a clean value dislocation.

Key Decisions for Investors

• Avoid initiating a long AHCO position for now; wait for evidence of FCF stabilization or a cleaner reset on the next quarterly print. Time horizon: 1-3 months.
• Short AHCO into any sharp post-earnings rebound or use a 3-6 month put spread if implied volatility remains below the expected earnings/catalyst volatility. Falsifier: management restores annual FCF guidance above ~$150M or shows clear sequential margin recovery.